NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma

NCT04594811 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

10

Enrollment

INDUSTRY

Sponsor class

Stopped Company strategic decision

Conditions

Gastric or Gastro-esophageal Junction (GEJ) or Esophageal Adenocarcinoma (EAC)

Interventions

DRUG: NT-I7
DRUG: Nivolumab

Sponsor

NeoImmuneTech

Collaborators

[object Object]